18 September 2026 - BEAM ALLIANCEPatients need more than one antimicrobial optionRead the full paper to explore why patient benefit, rather than a winner-takes-all approach, should remain at the heart of…
30 June 2026 - BEAM ALLIANCEBroad multidisciplinary coalition warns AMR threatens global health security and urges G7 leaders to make it a public health priorityA new international coalition of more than 60 experts and organisations is calling on G7 leaders to urgently take action…
16 June 2026 - BEAM ALLIANCEThe G7 presidency presents a unique opportunity for France to make antimicrobial resistance a strategic public health priorityAs the G7 meets in Evian (Haute-Savoie) from June 15 to 17, some fifty experts call on France, in an…
21 April 2026 - BEAM ALLIANCEIntegrating Biodefence into the European Competitiveness Fund: A Strategic ImperativeThis new paper highlights the urgent need to recognise antimicrobial resistance (AMR) as both a public health threat and a security…
3 March 2026 - BEAM ALLIANCEBEAM is turning 10!What a journey since the association was founded in 2016! Since then, awareness of the looming AMR problem has grown,…
11 December 2025 - BEAM ALLIANCEEU Reaches Landmark Agreement on Pharmaceutical Legislation RevisionAfter a long night of negotiations, EU co-legislators have reached a long-awaited political agreement on the revision of the Union’s…
14 September 2026 - Basilea Pharmaceutica InternationalBasilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patientsInvasive fungal infections pose a critical threat for children suffering from hematologic malignancies or immunodeficiency disorders.
7 September 2026 - VAXDYNVaxdyn raises €11M Series A to test AMR vaccineThis funding round marks a critical step in Vaxdyn’s evolution into a clinical-stage company, allowing us to clinically validate a…
2 September 2026 - BioVersysBioVersys granted Fast-Track Designation from US FDA for BV100This designation underscores the significant unmet medical need for new treatment options for patients suffering from serious infections caused by…
12 August 2026 - SNIPR BiomeExpanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious DiseasesThis case report marks an important clinical milestone for SNIPR001 and highlights the potential of our engineered CRISPR medicine platform…
5 August 2026 - Basilea Pharmaceutica InternationalBasilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactamBasilea has secured an additional USD 5.4 million from BARDA to accelerate the development of its novel oral antibiotic ceftibuten-ledaborbactam…
29 July 2026 - Basilea Pharmaceutica InternationalBasilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepixThe new tranche of USD 30 million comes in addition to the USD 93 million already committed by BARDA since…
9 November 2026BIO-Europe® 2026The must‑attend global life science partnering event where the biopharma C‑suite, investors and partners meet to set the industry agenda…
10 October 202610th Interdisciplinary Course on Antibiotics & Resistance (ICARe)The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…
29 September 2026REVIVE Webinar: The role of investigator initiated clinical trials in advancing antimicrobial useLeading investigators of clinical trials will present how evidence generation can support more effective, sustainable and accessible use of antibiotics.
22 September 2026GAMRIC – Global AMR Innovators ConferenceThe Global AMR Innovators Conference (GAMRIC) is an event that brings together researchers, academics, and industry professionals from around the…
17 September 2026REVIVE Webinar: Tackling pharmacokinetic and pharmacodynamic challenges in antifungal therapyThis webinar will discuss the recent advances to overcome the pharmacokinetic and pharmacodynamic challenges in antifungal treatment.
10 September 2026BEAM Alliance Webinar: Advancing AMR Innovation through European Funding, Partnerships and Clinical ResearchionThis webinar will be particularly relevant for innovators looking to prepare early for upcoming European opportunities and strengthen future collaborative…